Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Leukemia, Biphenotypic, Acute 5Sarcoma, Myeloid 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 10Azacitidine 10fludarabine phosphate 8Whole-Body Irradiation 8Cyclosporine 7ruxolitinib 6Mycophenolic Acid 6Busulfan 6Methotrexate 5Cyclophosphamide 5fludarabine 4Tacrolimus 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 3Alemtuzumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2eprenetapopt 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Docetaxel 2Cord Blood Stem Cell Transplantation 2tipifarnib 1sonidegib 1rucaparib 1quizartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloproliferative Disorders × Cladribine × Clear all
NCT02728050 2023-07-05

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

University of Washington

Phase 1/2 Completed
84 enrolled 28 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡